J Rosenstock, G Dailey, M Massi-Benedetti, A … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—Insulin glargine (LANTUS) is a once-daily basal insulin analog with
a smooth 24-h time-action profile that provides effective glycemic control with
reduced hypoglycemia risk (particularly nocturnal) compared with NPH ... Cited by 198 - Related articles - All 6 versions
HU Janka, G Plewe, MC Riddle, C Kliebe- … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, multinational, multicenter, open,
parallel group clinical trial, 371 insulin-naïve patients with poor glycemic
control (fasting blood glucose [FBG] ≥120 mg/dl, HbA 1c 7.5–10.5%) on ... Cited by 223 - Related articles - All 8 versions
H Yki-Järvinen, R Kauppinen-Mäkelin, M … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 442–451 DOI 10.1007/s00125-005-0132-0 ARTICLE H.
Yki-Järvinen . R. Kauppinen-Mäkelin . M. Tiikkainen . M. Vähätalo . ... Cited by 156 - Related articles - BL Direct - All 7 versions
P Raskin, E Allen, P Hollander, A Lewin, RA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—A total of 209 subjects completed the study. At study end, the mean
HbA 1c value was lower in the BIAsp 70/30 group than in the glargine group (6.91
± 1.17 vs. 7.41 ± 1.24%, P < 0.01). The HbA 1c reduction was greater in ... Cited by 326 - Related articles - All 7 versions
- Free from Publisher J Rosenstock, SL Schwartz, CM Clark Jr, GD … - Diabetes Care, 2001 - 万方数据资源系统 OBJECTIVE: To determine the safety and efficacy of the long-acting analog
insulin glargine compared with NPH insulin in patients with type 2 diabetes who
were previously treated with insulin alone. RESEARCH DESIGN AND METHODS: A ... Cited by 346 - Related articles - BL Direct - All 5 versions
K Hermansen, M Davies, T Derezinski, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and
from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of
participants achieved an A1C ≤7.0%, but the proportion achieving this ... Cited by 225 - Related articles - BL Direct - All 9 versions
M Massi Benedetti, E Humburg, A Dressler, … - Hormone and metabolic research, 2003 - cat.inist.fr Aims: The aim of the trial was to compare the efficacy and safety of the new,
long-acting basal insulin, insulin glargine(LANTUS®), with NPH human
insulin, each administered in a combination regimen with oral antidiabetic ... Cited by 105 - Related articles - BL Direct - All 2 versions
- ►annals.org [PDF] A Fritsche, MA Schweitzer, HU Haring… - Annals of internal medicine, 2003 - Am Coll Physicians Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral ...
Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients ... Andreas
Fritsche, MD; Matthias Axel Schweitzer, MD; Hans-Ulrich Häring, MD; and ... Cited by 160 - Related articles - BL Direct - All 7 versions
T Haak, A Tiengo, E Draeger, M Suntum, W … - Diabetes Obesity and Metabolism, 2005 - fe-inzichten.nl Aim: The aim of this study was to compare the efficacy and safety of a
basal-bolus insulin regimen comprising either insulin detemir or neural
protamine hagedorn (NPH) insulin in combination with mealtime insulin ... Cited by 193 - Related articles - View as HTML - All 5 versions
MC Riddle, J Rosenstock, J Gerich - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a randomized, open-label, parallel, 24-week
multicenter trial, 756 overweight men and women with inadequate glycemic control
(HbA 1c >7.5%) on one or two oral agents continued prestudy oral agents and ... Cited by 427 - Related articles - BL Direct - All 6 versions
